学术探索
学术期刊
新闻热点
数据分析
智能评审

Melanoma and Immunotherapy

被引：41
作者：
Eggermont, Alexander M. M. [1 ]
Schadendorf, Dirk [2 ]
机构：
[1] Erasmus Univ, Dept Surg Oncol, MC Daniel den Hoed Canc Ctr, NL-3075 EA Rotterdam, Netherlands
[2] Univ Hosp Essen, Dept Dermatol, D-45122 Essen, Germany
来源：
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2009年 / 23卷 / 03期
关键词：
Melanoma; Immunotherapy; Cytokines; Antibodies; Vaccines; Review; RANDOMIZED PHASE-III; METASTATIC MALIGNANT-MELANOMA; COOPERATIVE-ONCOLOGY-GROUP; TUMOR-INFILTRATING LYMPHOCYTES; HIGH-DOSE INTERLEUKIN-2; HIGH-RISK MELANOMA; STAGE-IV MELANOMA; CD8(+) T-CELLS; AMERICAN JOINT COMMITTEE; NODE-NEGATIVE MELANOMA;
D O I：
10.1016/j.hoc.2009.03.009
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
About 20% of all primary melanomas will spread. The likelihood of metastatic behavior correlates with prognostic factors such as tumor thickness, mitotic index, presence of ulceration, lymphocyte infiltration, age, gender, and anatomic site. Immunotherapies are developed for melanoma patients in stage IV who have distant metastases and in stage II to III patients in the adjuvant micrometastatic setting, where only a fraction of patients have widespread (microscopic) disease.
引用
收藏
页码：547 / +
页数：20
相关论文
共 118 条
  • [1] Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma
    Agarwala, SS
    Glaspy, J
    O'Day, SJ
    Mitchell, M
    Gutheil, J
    Whitman, E
    Gonzalez, R
    Hersh, E
    Feun, L
    Belt, R
    Meyskens, F
    Hellstrand, K
    Wood, D
    Kirkwood, JM
    Gehlsen, KR
    Naredi, P
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (01) : 125 - 133
  • [2] [Anonymous], J CLIN ONCOL
  • [3] High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993
    Atkins, MB
    Lotze, MT
    Dutcher, JP
    Fisher, RI
    Weiss, G
    Margolin, K
    Abrams, J
    Sznol, M
    Parkinson, D
    Hawkins, M
    Paradise, C
    Kunkel, L
    Rosenberg, SA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (07) : 2105 - 2116
  • [4] HYPOTHYROIDISM AFTER TREATMENT WITH INTERLEUKIN-2 AND LYMPHOKINE-ACTIVATED KILLER CELLS
    ATKINS, MB
    MIER, JW
    PARKINSON, DR
    GOULD, JA
    BERKMAN, EM
    KAPLAN, MM
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1988, 318 (24) : 1557 - 1563
  • [5] Phase III Trial Comparing Concurrent Biochemotherapy With Cisplatin, Vinblastine, Dacarbazine, Interleukin-2, and Interferon Alfa-2b With Cisplatin, Vinblastine, and Dacarbazine Alone in Patients With Metastatic Malignant Melanoma (E3695): A Trial Coordinated by the Eastern Cooperative Oncology Group
    Atkins, Michael B.
    Hsu, Jessie
    Lee, Sandra
    Cohen, Gary I.
    Flaherty, Lawrence E.
    Sosman, Jeffrey A.
    Sondak, Vernon K.
    Kirkwood, John M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (35) : 5748 - 5754
  • [6] Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4
    Attia, P
    Phan, GQ
    Maker, AV
    Robinson, MR
    Quezado, MM
    Yang, JC
    Sherry, RM
    Topalian, SL
    Kammula, US
    Royal, RE
    Restifo, NP
    Haworth, LR
    Levy, C
    Mavroukakis, SA
    Nichol, G
    Yellin, MJ
    Rosenberg, SA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) : 6043 - 6053
  • [7] Combination chemotherapy with or without s.c. IL-2 and IFN-α:: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM)
    Atzpodien, J
    Neuber, K
    Kamanabrou, D
    Fluck, M
    Bröcker, EB
    Neumann, C
    Rünger, TM
    Schuler, G
    von den Driesch, P
    Müller, I
    Paul, E
    Patzelt, T
    Reitz, M
    [J]. BRITISH JOURNAL OF CANCER, 2002, 86 (02) : 179 - 184
  • [8] MULTICENTER RANDOMIZED TRIAL OF DACARBAZINE ALONE OR IN COMBINATION WITH 2 DIFFERENT DOSES AND SCHEDULES OF INTERFERON ALFA-2A IN THE TREATMENT OF ADVANCED MELANOMA
    BAJETTA, E
    DILEO, A
    ZAMPINO, MG
    SERTOLI, MR
    COMELLA, G
    BARDUAGNI, M
    GIANNOTTI, B
    QUEIROLO, P
    TRIBBIA, G
    BERNENGO, MG
    MENICHETTI, ET
    PALMERI, S
    RUSSO, A
    CRISTOFOLINI, M
    ERBAZZI, A
    FOWST, C
    CRISCUOLO, D
    BUFALINO, R
    ZILEMBO, N
    CASCINELLI, N
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (04) : 806 - 811
  • [9] Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-α2b in metastatic melanoma
    Bajetta, E
    Del Vecchio, M
    Nova, P
    Fusi, A
    Daponte, A
    Sertoli, MR
    Queirolo, P
    Taveggia, P
    Bernengo, MG
    Legha, SS
    Formisano, B
    Cascinelli, N
    [J]. ANNALS OF ONCOLOGY, 2006, 17 (04) : 571 - 577
  • [10] Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma
    Balch, CM
    Buzaid, AC
    Soong, SJ
    Atkins, MB
    Cascinelli, N
    Coit, DG
    Fleming, ID
    Gershenwald, JE
    Houghton, A
    Kirkwood, JM
    McMasters, KM
    Mihm, MF
    Morton, DL
    Reintgen, DS
    Ross, MI
    Sober, A
    Thompson, JA
    Thompson, JF
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (16) : 3635 - 3648
12345678910